Aug 03, 2006
|
Vertex Pharmaceuticals Announces Agreements to Exchange Common Stock for $58.3 Million of its Convertible Senior Subordinated Notes Due 2011
|
|
Jul 26, 2006
|
Vertex Pharmaceuticals Reports Second Quarter 2006 Financial Results
|
|
Jun 30, 2006
|
Vertex Pharmaceuticals and Tibotec Pharmaceuticals, a Johnson & Johnson Company, Announce Plans for Global Health Initiative to Increase Worldwide Prevention, Diagnosis and Treatment of HCV
|
|
Jun 30, 2006
|
Vertex Pharmaceuticals and Janssen Pharmaceutica, a Johnson & Johnson Company, Form Collaboration to Develop and Commercialize VX-950 for Treatment of Hepatitis C
|
|
May 23, 2006
|
Vertex Pharmaceuticals Initiates the First of Two Major Phase II Studies of VX-950 in Treatment-Naïve HCV Patients
|
|
May 21, 2006
|
Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients
|
|
May 17, 2006
|
Vertex Pharmaceuticals Initiates Phase I Development for VX-770 in Cystic Fibrosis
|
|
May 16, 2006
|
GlaxoSmithKline and Vertex Pharmaceuticals Announce Preliminary 48-Week Results from Head-to-Head Clinical Study of HIV Protease Inhibitors Lexiva (Telzir) and Kaletra in Treatment-naive Patients with HIV
|
|
May 11, 2006
|
Stockholders of Vertex Pharmaceuticals Approve Proxy Proposals at Annual Meeting
|
|
Apr 29, 2006
|
Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients
|
|
Apr 26, 2006
|
New Data Highlight Anti-HCV Activity of Investigational Oral Hepatitis C Protease Inhibitor VX-950
|
|
Apr 25, 2006
|
Vertex Pharmaceuticals Reports First Quarter 2006 Financial Results
|
|
Apr 05, 2006
|
Vertex Pharmaceuticals Announces Initiation of Phase II Development Program for Aurora Kinase Inhibitor MK-0457 (VX-680)
|
|
Mar 23, 2006
|
Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Enter Collaboration to Develop Oral Drug Candidate VX-770 for CF
|
|
Mar 08, 2006
|
Vertex Reports Investigational p38 MAP Kinase Inhibitor, VX-702, Meets Primary Objectives in Phase II Clinical Study in Rheumatoid Arthritis
|
|
Feb 23, 2006
|
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Citigroup 2006 Healthcare Conference
|
|
Feb 07, 2006
|
Vertex Successfully Completes Key Studies with VX-950 to Prepare for Next Steps in Clinical Program
|
|
Feb 06, 2006
|
Vertex Pharmaceuticals Reports 2005 Financial Results
|
|
Jan 12, 2006
|
Vertex Pharmaceuticals and Cystic Fibrosis Foundation Therapeutics Extend Collaboration for Cystic Fibrosis Drug Research
|
|
Jan 09, 2006
|
Vertex Pharmaceuticals Announces Key Business Objectives for 2006 at 24th Annual JPMorgan Healthcare Conference
|
|